Viral hepatitis

Hepatology

Volumn 43, Issue 2 SUPPL. 1, 2006, Pages

  Alter, Harvey ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

DRUG DOSE REGIMEN; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; LIVER FIBROSIS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS;

DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 33644507139     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21030     Document Type: Review

References (35)

1. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
2. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes J Exp Med 2003;197:633-642.
3. Meunier J-C, Engle RE, Faulk K, Zhao M, Bartosch B, Alter HJ, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo particles and enhancement of infectivity by apolipoprotein C1. PNAS 2005;102:4560-4565.
4. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. HEPATOLOGY 2005;41:265-274.
5. Girard S, Vossman E, Misek DE, Podevin P, Hanash S, Brechot C, et al. Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. HEPATOLOGY 2004;40:708-718.
6. Wiese M, Grungreiff K, Gusthoff W, Lafranz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25 year multicenter study. J Hepatol 2005;43:590-598.
7. Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. HEPATOLOGY 2002;36:993-1000.
8. Casiraghi MA, De Paschale M, Romano L, Biffi R, Assi A, Binelli G, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004;39:90-96.
9. Rai R, Wilson LE, Astemborski J, Anania F, Torbenson M, Spoler C, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. HEPATOLOGY 2002;35:1247-1255.
10. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. HEPALOLOGY 2001;34:1193-1199.
11. Tanaka Y, Hanada K, Mizokami M, Yeo AET, Shih JW, Gojoboti T, et al. A comparison of molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the US will increase over rhe next two decades. PNAS 2002;99:15584-15589.
12. Kamegaya Y, Hiasa Y, Zukerberg L, Fowler N, Blackard JT, Lin W, et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. HEPATOLOGY 2005;41:660-667.
13. Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. HEPATOLOGY 2003;1189-1198.
14. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD84+ T cell responses during longitudinal study of acute human hepatitis C. HEPATOLOGY 2005;42:104-112.
15. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. HEPATOLOGY 2003;38:1437-1448.
16. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. HEPATOLOGY 2004;40:1062-1071.
17. Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M, et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. HEPATOLOGY 2005;42:828-837.
18. Penna A, Missale G, Lamonaca V, Pilli M, Mori C, Zanelli P, et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. HEPATOLOGY 2002;35:1225-1236.
19. Zhang T, Lin R-T, Li Y, Dogulas SD, Maxcey C, Ho C, et al. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. HEPATOLOGY 2005;42:819-827.
20. Foy E, Li K, Sumpter R Jr, Loo Y-M, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-1 signaling. PNAS 2005;102:2986-2991.
21. Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dhatel N, et al. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. HEPATOLOGY 2005;41:1004-1012.
22. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. HEPATOLOGY 2005;41:809-818.
23. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. HEPATOLOGY 2002;36:729-736.
24. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. HEPATOLOGY 2002;36:978-985.
25. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003;38:518-526.
26. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003;38:481-492.
27. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. HEPATOLOGY 2002;36:973-977.
28. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002;36:986-992.
29. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. HEPATOLOGY 2005;42:282-292.
30. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2005;41:48-54.
31. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. HEPATOLOGY 2005;42:838-845.
32. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. HEPATOLOGY 2005;41:106-114.
33. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. HEPATOLOGY 2005;41:275-279.
34. McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. HEPATOLOGY 2003;38:503-508.
35. Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. HEPATOLOGY 2003;38:842-850.